Here are three things to know.
1. Lokelma is intended to treat patients with hyperkalemia, a condition involving elevated potassium levels in the blood.
2. AstraZeneca gained the rights to the drug through its $2.7 billion acquisition of ZS Pharma in 2015, according to Reuters.
3. Lokelma will compete with Vifor Pharma’s drug Veltassa, also used to treat hyperkalemia.
More articles on supply chain:
Vermont first state to legalize drug importation from Canada
6 key proposals unveiled in Trump’s plan to combat rising drug costs
62% of hospital leaders support Amazon as a medical supplier
